Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
The leading professional organisation for medical oncology
The most influential oncology platform to share your research
Join this live discussion and ask your questions to the experts developing and implementing the ESMO Guidelines
A live discussion on the efficacy of SARS-CoV-2 vaccines in cancer patients while new variants are emerging
A comprehensive update of all key developments in the field
Now available on-demand. Take the CME test and advance your knowledge in upper digestive cancers
Do not miss this opportunity and submit your application by 23 March 2022
A validated and reproducible tool to assess the magnitude of clinical benefit for cancer medicines.
An in-depth reflection on gaps in medical knowledge and research with Emmanouil Saloustros and Liz Margolies
From 2022 ASCO Genitourinary Cancers Symposium
Longer follow-up of the phase III study shows a consistent disease-free survival benefit with the postsurgical use of pembrolizumab in patients with renal cell carcinoma and high-risk features
Findings from the randomised, phase III STELLAR study
ESMO would like to thank the National Oncology Institute in Bratislava for providing translation in the Slovak language
Patients must be selected for therapy based on an FDA-approved companion diagnostic for olaparib
It is intended for the treatment of adult patients with urothelial cancer
The European Lung Cancer Congress 2022 (ELCC), the annual event dedicated to advancing the science, disseminating education and improving the practice of lung cancer specialists worldwide, will be held as a virtual meeting.
Findings from a large, prospective cohort study of patients with inflammatory bowel disease diagnosed in Norway and Sweden
Original data presentations by the authors of the OlympiA and PEARLS/KEYNOTE-091 trials will be followed by critical analysis and discussion with a panel of renowned experts.
Findings from the first population-based study to examine SARS-CoV-2 infections in survivors of childhood, adolescent, and young adult cancer compared with matched population controls
Efficacy was evaluated in CHECKMATE-816 study
The tyrosine kinase inhibitor shows signs of efficacy in treatment-naïve NSCLC with HER2 exon 20 insertions, but its safety profile remains a limiting factor
Blocking the tyrosine kinase cell-cycle progression regulator WEE1 may help to reinstate tumour immunogenicity and potentiate the effects of immune checkpoint inhibitors
Novel scheduling of RP-3500 mitigates haematological toxicity and may facilitate combination therapy but tumour types most likely to respond remain to be defined
A greater understanding of the complexity of breast cancer, in all its forms, is key to better patient selection, new target development and improved outcomes, says Prof. Fabrice André
Early-phase trials suggest that sitravatinib may reboot the tumour response to PD-1 inhibitors, but confirmation of efficacy is required and strategies are needed to adjust tolerability
Developing therapies for cancers harbouring KRAS mutations has proven difficult but PROTACs, acting via targeted protein degradation, may help combat previously undruggable proteins
In her keynote lecture at the ESMO Targeted Anticancer Therapies Congress 2022, Prof. Lesley Seymour stresses the importance of sharing ideas and resources between academia and industry
Achieving clarity in levels of clinical evidence required by regulatory bodies is still a major obstacle to expediting research in the field, says Prof. Paolo G. Casali from the Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, and the University of Milan, Italy
Proteomic research on sarcomas is only in its infancy, but it offers potential in terms of improved biological understanding, identification of new treatment targets and generating biomarkers for patient selection and prognosis prediction
Findings from the randomised, phase III STELLAR study
Patients must be selected for therapy based on an FDA-approved companion diagnostic for olaparib
It is intended for the treatment of adult patients with urothelial cancer
Findings from a large, prospective cohort study of patients with inflammatory bowel disease diagnosed in Norway and Sweden
Findings from the first population-based study to examine SARS-CoV-2 infections in survivors of childhood, adolescent, and young adult cancer compared with matched population controls
Efficacy was evaluated in CHECKMATE-816 study
Classifications is proposed according sensitivity of atypical EGFR mutations to tyrosine kinase inhibitors
New indication concerns the use in patients with early breast cancer at high risk of recurrence
Promising clinical benefit associated with an enrichment of bacterial species, circulating cytokines and immune cell populations in responders
The European Lung Cancer Congress 2022 (ELCC), the annual event dedicated to advancing the science, disseminating education and improving the practice of lung cancer specialists worldwide, will be held as a virtual meeting.
Original data presentations by the authors of the OlympiA and PEARLS/KEYNOTE-091 trials will be followed by critical analysis and discussion with a panel of renowned experts.
ESMO announces a new series of resources designed to guide physicians in areas of oncological practice not covered by guidelines, where current evidence is insufficient to evenly inform clinical decision-making
The ESMO Targeted Anticancer Therapies Congress 2022, designed for basic scientists, physicians and translational researchers belonging to academic settings, industry and regulatory agencies will be held as a virtual meeting.
Open-source approach leveraging ESMO tools can inform sustainable healthcare spending to benefit national populations worldwide
Death rates from ovarian cancer are predicted to fall by 17% in 2022 in the UK and by 7% in EU countries in 2022 compared to 2017
The ESMO Sarcoma & GIST Symposium 2022, will be held as a virtual event.
The ESMO Immuno-Oncology Congress 2021, the European platform dedicated to the development and use of immunotherapies for cancer treatment, will be held as an onsite and online congress.
In light of the challenging situation in Prague due to the ongoing arrival of refugees from Ukraine
ESMO expresses profound sadness about the unfolding tragedy in Ukraine and the suffering of people
The 2022 ESMO Heine H. Hansen Award is conferred on Fred R. Hirsch for his lifelong outstanding contribution to lung cancer research
Who will be the next ESMO Awardees? Submit your nominations before 9 March.
ESMO has announced today that the 2022 ESMO TAT Honorary Award is presented to Lesley K Seymour
Based on current knowledge available, they address key questions on safety and efficacy of COVID-19 vaccines, their interference with anticancer treatment, and advocate for a global strategy for the booster dose
ESMO President will act as an Advisor
ESMO delivered an official statement at the Special Session of the World Health Assembly to strengthen pandemic prevention, preparedness and response
The ESMO Immuno-Oncology Congress will be an online-only meeting
Supporting your clinical decisions with ESMO’s regularly updated Clinical Practice Guidelines and consensus recommendations, developed by the leading experts in our profession.
Resources such as abstracts, presentations and webcasts from meetings can be accessed by ESMO members and conference delegates throughout all the year
The courses include state of the art lectures, workshops and interactive discussion seminars
A globally visible platform to publish scientific studies and a source of educational updates.
A range of publications that can be browsed online by all ESMO members and downloaded for offline use
Mexico
Mexico
Germany
Spain
Belgium
Spain
Participate in our collegial events with leaders in the field and get the chance to collaborate
with prominent European cancer institutions.
Take the CME test with E-learning and V-learning modules
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
